GlassScriptPhysician profile
Luzviminda Alexander
NPI 1841632437
$10,112.19
in general payments reported to CMS, 2019-2025
27 companies · $2,500 in 2025
The $2,500 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $675 · 2022: $1,435 · 2023: $3,100 · 2024: $2,402 · 2025: $2,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,002.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,680.79 | 2021-2025 | Cardiomems, Gallant, Diamondback Peripheral |
| Scpharmaceuticals INC. | $878.25 | 2023-2025 | |
| Abiomed | $871.31 | 2022-2025 | Impella |
| Kestra Medical Technology Services, INC. | $777.70 | 2024-2025 | Assure Wcd |
| Cvrx, INC. | $742.01 | 2022-2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $531.36 | 2021-2025 | Farxiga, Lokelma, Andexxa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $418.32 | 2021-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $388.72 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $385.41 | 2022-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $313.14 | 2023-2025 | |
| Novo Nordisk INC | $294.44 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Bridgebio Pharma, INC. | $266.55 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $232.69 | 2021-2025 | Amvuttra |
| Pfizer INC. | $230.19 | 2023-2025 | |
| Lantheus Medical Imaging, INC. | $223.59 | 2021-2025 | Definity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $132.00 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lexicon Pharmaceuticals, INC. | $129.98 | 2023-2024 | Inpefa |
| Lilly USA, LLC | $123.55 | 2023 | Mounjaro |
| Boston Scientific Corporation | $119.55 | 2023 | Wolverine Coronary Cutting Balloon, Watchman Flx |
| Heartflow, INC. | $90.07 | 2023 | Ffrct |
| Bayer Healthcare Pharmaceuticals INC. | $81.22 | 2025 | |
| Impulse Dynamics (USA) INC. | $76.03 | 2022 | |
| Esperion Therapeutics, INC. | $42.86 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.91 | 2023 | Jardiance |
| Amgen INC. | $18.04 | 2024 | Repatha |
| Shockwave Medical, INC | $17.85 | 2025 | |
| Philips North America LLC | $13.66 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luzviminda Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.